Merck is racing to defend its leadership in the market for cancer drugs ahead of Keytruda’s looming patent cliff. A clinical ...

Go behind the scenes of the Cancer Calculus investigation, and hear insights about Merck's cancer drug Keytruda from ICIJ's ...

Spot and Tubular data show prescription immunology brands continued to dominate TV, while seasonal OTC brands found scale on ...

Democrats face an uphill battle to win the Senate. They see in Mary Peltola, the first Native Alaskan elected to Congress, ...

I agree to the Terms of Use , Privacy Notice and Cookie Notice. I would like to receive updates and special offers from Dow Jones and affiliates. I can unsubscribe at any time.

The late-stage miss shakes analyst confidence in Regeneron’s clinical execution, according to BMO Capital Markets, also ...

An Orange County judge has banned all Kars4Kids ads, including the earworm of a jingle, from broadcasting in the state of California after finding that the charity violated false advertising and ...

Eli Lilly’s diabetes drug Mounjaro has become the world’s top-selling medication, surpassing Merck’s cancer therapy Keytruda. Lilly’s performance compounded when Mounjaro and weight-loss drug Zepbound ...

When will we have another “Sleepless in Seattle”? Or the next “10 Things I Hate About You”? For years, local film buffs have yearned for Seattle’s golden age of cinema — the era in the late 20th ...

Merck reported higher first-quarter sales and raised its full-year earnings guidance as demand for its flagship Keytruda cancer drug continues to grow. Sales rose 5% to $16.29 billion, boosted by 12% ...

On the Wednesday, April 15, 2026, episode of The Excerpt podcast: Prices for cutting-edge medical treatments can balloon in the U.S. health care system, leading to higher costs for the employer, ...

Merck will acquire Terns for $53 per share in cash, amounting to an equity value of about $6.7 billion. This is the third multibillion-dollar acquisition for Merck over the past year as it looks to ...